<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336244</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG0778-CL-102</org_study_id>
    <secondary_id>2011-000892-16</secondary_id>
    <nct_id>NCT01336244</nct_id>
  </id_info>
  <brief_title>GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study</brief_title>
  <official_title>Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of GLPG0778 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and tolerability of multiple ascending
      oral doses (MAD) of GLPG0778 given to healthy subjects for 13 days compared to placebo, and
      to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0778 after multiple
      oral administrations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>Daily during treatment, up to 10 days postdose</time_frame>
    <description>At every study visit, subjects will be asked whether any adverse events have occurred since start of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of hematological, biochemical and cardiovascular parameters.</measure>
    <time_frame>until 10 days postdose.</time_frame>
    <description>On predefined timepoints during the study blood and urine samples will be taken, and cardiovascular tests (ECG, blood pressure, heart rate) recorded to assess whether the test compound causes any deviation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of repeated doses</measure>
    <time_frame>24 hours postdose</time_frame>
    <description>Bloodsamples are taken on various timepoints to assess how much of the study drug is taken up in the blood (absorption), how long it stays in the blood (excretion), and whether any &quot;breakdown&quot;-products of the drug are present (metabolism).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD) of GLPG0778</measure>
    <time_frame>up to 10 days postdose</time_frame>
    <description>To explore biomarkers of GLPG0778 activity after repeated oral administrations.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLPG0778 ascending doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending doses for 13 days, ranging from 50 mg twice daily upto a maximum to be determined during escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily for 13 days, matching the scheme of the multiple ascending dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG0778</intervention_name>
    <description>capsules containing 50 or 100 mg of GLPG0778</description>
    <arm_group_label>GLPG0778 ascending doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male, age 18-50 years

          -  body mass index (BMI) between 18-30 kg/mÂ², inclusive.

        Exclusion Criteria:

          -  significantly abnormal platelet function or coagulopathy

          -  smoking

          -  drug or alcohol abuse

          -  hypersensitivity to any of the test substances
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerben van 't Klooster, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lien Gheyle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS Stuivenberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Stuivenberg</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2011</study_first_posted>
  <last_update_submitted>October 17, 2011</last_update_submitted>
  <last_update_submitted_qc>October 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

